Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLR1044 biosimilar to Dupixent in healthy Chinese males
NCT07334496Phase 1Not yet recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dupilumab (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve from Time Zero to Infinity. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
Beyond the preview
Go deeper on NCT07334496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334496.